GSK5784283

GSK5784283 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Pulmonary Disease, Chronic Obstructive、Asthma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 GSK5784283 研究

• A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

  III 期招募中美国Puerto RicoNCT07782970

• A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)

  III 期招募中美国NCT07782996

• A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)

  III 期招募中美国NCT07780643

• A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

  III 期招募中美国NCT07780669

• A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283

  I 期招募中美国NCT07712393

• A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

  III 期招募中美国澳大利亚NCT07782957

• A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)

  III 期招募中美国NCT07780656

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。